Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis

被引:116
作者
Kim, WJ
Yockman, JW
Lee, M
Jeong, JH
Kim, YH
Kim, SW
机构
[1] Univ Utah, Ctr Controlled Chem Delivery, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA
[2] Hanyang Univ, Coll Engn, Dept Bioengn, Seoul 133791, South Korea
关键词
gene therapy; anti-angiogenesis; RGD peptide; soluble Flt-1; VEGF;
D O I
10.1016/j.jconrel.2005.04.016
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Vascular endothelial growth factor (VEGF), a potent angiogenic molecule specific for vascular endothelial cells, is overexpressed in most tumors and closely associated with tumor growth and metastasis. It has been shown that a soluble fragment of VEGF receptor Flt-1 (sFIt-1) has anti-angiogenic properties by way of its antagonist activity against VEGF. In the present study, we demonstrated that the stable expression of sFIt-1 by endothelial cell targeted non-viral gene delivery inhibited the angiogenesis of endothelial cells. A targeted polymeric gene delivery system, PEI-g-PEG-RGD, was developed by incorporating the alpha v beta 3/alpha v beta 5 integrin-binding RGD peptide, ACDCRGDCFC (single-letter amino acid code), into the cationic polymer, polyethylenimine (PEI) via a hydrophilic polyethylene glycol (PEG) spacer. The functional analysis of therapeutic gene encoding sFIt-1/carrier complex was performed with an endothelial cell proliferation assay. The complex of sFlt-1 gene with PEI-g-PEG-RGD conjugate efficiently inhibited the proliferation of cultured endothelial cells, representing that expressed sFIt-1 predominantly bound to exogenous VEGF and blocked the binding of VEGF to the full-length Flt-1 receptor. These findings suggest that the combination of targeted gene carrier and sFlt-1 possesses the potential to be an efficient tool for the anti-angiogenic gene therapy to treat cancer. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:224 / 234
页数:11
相关论文
共 38 条
[31]   VASCULAR ENDOTHELIAL GROWTH-FACTOR - A NEW MEMBER OF THE PLATELET-DERIVED GROWTH-FACTOR GENE FAMILY [J].
TISCHER, E ;
GOSPODAROWICZ, D ;
MITCHELL, R ;
SILVA, M ;
SCHILLING, J ;
LAU, K ;
CRISP, T ;
FIDDES, JC ;
ABRAHAM, JA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 165 (03) :1198-1206
[32]   PEPTIDES DERIVED FROM 2 SEPARATE DOMAINS OF THE MATRIX PROTEIN THROMBOSPONDIN-1 HAVE ANTI-ANGIOGENIC ACTIVITY [J].
TOLSMA, SS ;
VOLPERT, OV ;
GOOD, DJ ;
FRAZIER, WA ;
POLVERINI, PJ ;
BOUCK, N .
JOURNAL OF CELL BIOLOGY, 1993, 122 (02) :497-511
[33]   A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1 [J].
Volpert, OV ;
Lawler, J ;
Bouck, NP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (11) :6343-6348
[34]   REGULATION BY VASCULAR ENDOTHELIAL GROWTH-FACTOR OF HUMAN COLON-CANCER TUMORIGENESIS IN A MOUSE MODEL OF EXPERIMENTAL LIVER METASTASIS [J].
WARREN, RS ;
YUAN, H ;
MATLI, MR ;
GILLETT, NA ;
FERRARA, N .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (04) :1789-1797
[35]   INTEGRIN-ALPHA-V-BETA-3 AND INTEGRIN-ALPHA-V-BETA-5 PROMOTE ADENOVIRUS INTERNALIZATION BUT NOT VIRUS ATTACHMENT [J].
WICKHAM, TJ ;
MATHIAS, P ;
CHERESH, DA ;
NEMEROW, GR .
CELL, 1993, 73 (02) :309-319
[36]   Sterically stabilized polyplex: ligand-mediated activity [J].
Woodle, MC ;
Scaria, P ;
Ganesh, S ;
Subramanian, K ;
Titmas, R ;
Cheng, C ;
Yang, J ;
Pan, Y ;
Weng, K ;
Gu, C ;
Torkelson, S .
JOURNAL OF CONTROLLED RELEASE, 2001, 74 (1-3) :309-311
[37]  
Yokoyama Y, 2000, CANCER RES, V60, P2190
[38]   Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor vascular permeability factor antibody [J].
Yuan, F ;
Chen, Y ;
Dellian, M ;
Safabakhsh, N ;
Ferrara, N ;
Jain, RK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) :14765-14770